The peak sales potential for all rotavirus vaccines was estimated to be $1.2 bn in a 2006 report by Morgan Stanley. The recent addition of rotavirus vaccine to the routine childhood immunization schedule by the CDC’s Advisory Committee on Immunization Practices (ACIP) is expected to revise the market size upward. Rotavax™'s annual sales will benefit from having much simpler storage requirements, i.e., stability outside the refrigerator, and a convenient one-step administration of a thin film on the tongue of the infant.